Metabolomics Market

Global Metabolomics Market Size (2024 to 2032)

The size of the global metabolomics market is estimated to grow to USD 11034 million by 2032 from USD 2744 million in 2024, growing at a CAGR of 19% during the forecast period.

Metabolomics is the substantial scale research of little atoms, ordinarily known as metabolites, inside cells, biofluids, tissues, or living beings. Aggregately, these tiny particles and their associations inside an organic framework are known as the metabolome. Metabolomics is a capable approach since metabolites and their concentration, unlike other "omics" measures, straightforwardly reflect cells/tissues' hidden biochemical movement and condition of cells/tissues. Consequently, metabolomics represents the atomic phenotype. Consequently, the global Metabolomics market is developing at a rapid pace.

MARKET DRIVERS

An increase in the acceptance of metabolomics in personalized medicines is one of the key variables boosting the global metabolomics market growth.

The expanding biotech innovative work and pharmaceutical consumption prompt persistent headways in innovation and spelling development for the worldwide metabolomics market. Then again, there are issues concerning information handling and information examination, representing a test for the market. Increasing demand for personalized medicines is expected to boost the growth opportunities for the metabolomics market. Furthermore, the increasing frequency of chronic degenerative diseases like cancer, cardiovascular diseases, and neurological disorders is likely to offer lucrative growth opportunities for the growth of the global metabolomics market. Furthermore, increasing economies of developing countries such as China, India, Brazil, and the Middle East will likely offer key stakeholders opportunities. In addition, the emergence of novel and innovative products due to technological developments immensely biomarkers contributes to the market's growth. Therefore, it is anticipated to create more opportunities for the growth of the world metabolomics market during the forecast period.

MARKET RESTRAINTS

The high cost of instruments and devices is expected to hamper the global metabolomics market's growth rate slightly.

Further, the requirement for very qualified specialists and the absence of the same limits the development of the metabolomics market. But, be that as it may, the undiscovered markets in rising countries will open doors for market players.

REPORT COVERAGE

SEGMENTAL ANALYSIS

Global Metabolomics Market Analysis By Product

The metabolomics instruments segment is forecasted to be the most lucrative segment among all in the global metabolomics market, and it has contributed the highest share. The adoption of metabolomics is increasing rapidly due to smooth technological operations leading to high workflow efficiency. In addition, other factors, such as reliability, precision, and data processing, are highly transparent and propel the growth of the metabolomics instruments segment.

Global Metabolomics Market Analysis By Application

The biomarker discovery segment has contributed a significant share in the overall revenue of the world metabolomics market. It is expected to be a rapidly growing segment among the applications during the forecast period. The adoption of metabolic biomarkers is consistently increasing for controlling diseases at the metabolic level due to enhanced reliability and efficiency, eventually leading to the growth of the biomarker discovery market. Furthermore, collaborations between biotechnology firms and pharmaceutical companies to validate and discover biomarkers are likely to propel the development of the personalized medicine segment during the forecast period.

REGIONAL ANALYSIS

North America led the market by capturing 38.7% of the global market share in 2023.

The existence of major participants in the metabolomics industry in the United States, growing biomedical research in the United States, and growing preclinical activities by CROs and pharmaceutical companies in the region all contribute to the region's prominent position. In addition, the presence of high per capita healthcare expenditures, rising adoption rates of healthcare technology, a well-established direct sales channel across the region, and a continuous boost to small and mid-sized metabolomics-oriented research communities and companies from the National Institutes of Health (NIH) program, all contribute to the metabolomics industry's growth. In the future, metabolomics is anticipated to enhance drug discovery and customized therapy, particularly in high-demand illness areas, including cardiovascular and metabolic disorders, cancer, mental health, and other infectious diseases. High product commercialization rates and advanced healthcare-related research and development activities are some of the causes contributing to the company's substantial market share.

Europe is estimated to grow at a CAGR of 18.4% during the forecast period

The financing from the governments and private funding in favour of metabolomics reassure the growth of the European market. Metabolomics has gradually been sought after as it helps shrink the hole between genotype and phenotype by offering a whole perspective of the cell working. Stable, innovative advances and investigations will guarantee a proceed with the development of this market and decrease these restrictions' effect in the future. Nonetheless, the unexplored markets in evolving countries will spur new progress and open doors for market players.

The Asia Pacific is the second-largest region and is likely to register the highest CAGR during the forecast period.

The growth of the Asia-Pacific market is majorly due to the growing demand for improved pharmaceutical goods from developing economies such as India and China, one of the market's most significant growth contributors. Because of key players in the Metabolomics Market, the Asia Pacific region is anticipated to expand at a significant CAGR during the forecast period. In addition, the rising aging population and rising instances of a wide range of illnesses have created possibilities for pharmaceutical firms in the area, propelling the metabolomics industry in the Asia Pacific region. Other factors contributing to market expansion in the Asia-Pacific region include growing demand for healthcare facilities, enhanced healthcare, and investments in life sciences that have opened up new avenues for market growth. Furthermore, mergers and partnerships between different government entities in terms of R&D efforts in metabolomics are taking place in nations like India. Additionally, both private and governmental entities have increased their investments. These factors are expected to have a favorable influence on India's metabolomics market growth. In countries such as Australia, there has been an increase in healthcare spending. Furthermore, Australia has a well-established infrastructure and expanding access to high-end technology in several industries. As a result, these factors are expected to enhance the metabolomics market growth in Australia.

The Latin American region is predicted to showcase a steady CAGR during the forecast period.

Govt. subsidizing is moreover reassuring the development of this market. Metabolomics is in effect progressively sought after as they help reduce the hole amongst genotype and phenotype by offering a total perspective of the cell working. It additionally helps in the recognizable proof of novel changes in a portion of the metabolites. The market is anticipated to keep thriving in both created and created districts. The development is additionally credited to the developing interest in metabolomics. The Latin American metabolomics market is developing at an exceptionally rapid speed.

MEA is anticipated to register a moderate growth rate in the coming years.

The metabolomics market in the Middle East & Africa is boosting due to factors like the emerging recognition of metabolomics in customized medicines. The expanding biotech innovative work and pharmaceutical consumption prompt persistent headways in innovation and spelling development for the worldwide metabolomics market. The unexplored markets in rising countries will goad new development open doors for market players. Further, the requirement for precisely qualified specialists and the lack of the same limits the expansion of the metabolomics market. The Middle East and Africa's Metabolomics market are evolving rapidly.

KEY PARTICIPANTS IN THE GLOBAL METABOLOMICS MARKET

Some of the prominent companies playing a significant role in the global metabolomics market profiled in the report are Agilent Technologies, Inc. (U.S.), Human Metabolome Technologies, Inc. (Japan), Thermo Fisher Scientific, Inc. (U.S.), LECO Corporation (U.S.), Bruker Corporation (U.S.), Shimadzu Corporation (Japan), Metabolon Inc. (U.S.), Danaher Corporation (U.S.), Biocrates Life Sciences AG (Austria), and Waters Corporation (U.S.)

RECENT HAPPENINGS IN THE GLOBAL MARKET

• In April 2019, Agilent Company launched new products for the laboratories associated with metabolomics research, food testing, environmental screening, and various analytical pursuits. Products are designed mainly for improving the efficiency of analytical and business outcomes.
• Metabolon Inc. has expanded its services and product portfolio regarding metabolomics by acquiring Metabolomic Discoveries GmbH in 2017.
• Murdoch University entered into a strategic collaboration with Bruker Company in September 2019. The primary objective of this collaboration is to develop phenomics for the diagnosis of diseases and enhance personalized health.

DETAILED SEGMENTATION OF THE GLOBAL METABOLOMICS MARKET INCLUDED IN THIS REPORT

This research report on the global metabolomics market has been segmented and sub-segmented based on the product, technology, and region.

By Product

• Metabolomic Instruments                               
  • Separation Techniques   
    • Gas Chromatography (GC)
    • Capillary Electrophoresis (CE)
    • High-performance Liquid Chromatography (HPLC)
    • Ultra-performance Liquid Chromatography (UPLC)
  • Detection Tools 
    • Mass Spectrometry
    • Nuclear Magnetic Resonance Spectroscopy
    • Surface-Based Mass Analysis
• Metabolomics Bioinformatics Tools and Services                  
  • Bioinformatics Tools & Databases              
  • Bioinformatics Services

By Indication

• Cancer
• Cardiovascular Disorders
• Inborn errors
• Neurological Errors
• Other Indications

By Application

• Nutrigenomics
• Toxicology
• Biomarker & Drug Discovery
• Functional Genomics
• Personalized Medicine
• Other Applications

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• The Middle East and Africa